t
PureTech Health plc announced that restricted share units (RSUs) granted on 19 November 2025 to five non-executive directors (PDMRs) vested in full on 9 June 2026. On 29 July 2026, the Company issued a total of 469,720 ordinary shares at 0.01 GBP each to these directors in settlement of the vested RSUs. Following this transaction, PureTech Health plc's total issued ordinary share capital is 257,927,489 shares, with 13,552,467 shares held in treasury.
| Date | 31 Jul 2026 |
| Time | 17:00:01 |
| Category | Director/PDMR dealings |
| ID | 8367O |
31 July 2026
PureTech Health plc
PDMR Notifications
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that awards of restricted share units ("RSUs") granted by PureTech on 19 November 2025 to certain non-executive directors ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 9 June 2026 the day immediately preceding the Company's Annual General Meeting of Stockholders. Each PDMR received vested ordinary shares on 29 July 2026.
The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 13,552,467 shares of which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||||||||||||||||
|
a) |
Name |
John LaMattina Robert Langer Kiran Mazumdar-Shaw Sharon Barber-Lui Michele Holcomb
|
|||||||||||||||||||||
|
2 |
Reason for the notification |
||||||||||||||||||||||
|
a) |
Position/status |
Non-Executive Directors |
|||||||||||||||||||||
|
b) |
Initial notification/Amendment |
Initial Notification |
|||||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||||||||||||||
|
a) |
Name |
PureTech Health plc |
|||||||||||||||||||||
|
b) |
LEI |
213800LVPDNO2Z9T9I39 |
|||||||||||||||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||||||||||||||
|
a) |
Description of the financial instrument, type of instrument |
|
|||||||||||||||||||||
|
b) |
Nature of the transaction |
Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan. |
|||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||||||||||||||
|
d) |
Aggregated information
|
|
|||||||||||||||||||||
|
e) |
Date of the transaction |
29 July 2026 |
|||||||||||||||||||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||||||||||||||||||||
About PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.
For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations